INTRODUCTION
I mpaired endothelium-dependent vasodilation, a hallmark of arterial hypertension (AH) and many other cardiovascular disease risk factors and disease conditions, can be an early mechanism leading to cardiovascular damage or, alternatively, a marker of it. Endothelial dysfunction in glomeruli and peritubular vessels affects filtration fraction, resulting in a progressive reduction in the glomerular filtration rate (GFR), extracellular fluid volume expansion, abnormal ion balance and renal hypoxia, all of which ultimately contribute to the age-dependent renal function loss in the hypertensive population and can lead to chronic kidney disease (CKD) [1] . Proteinuria, a marker of renal microvasculature damage, is invariably associated with systemic endothelial dysfunction in hypertension, suggesting a general involvement of the endothelium [2] .
After examining in Part I the general mechanisms underlying endothelial dysfunction in the kidney, using the same methodology, the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension in conjunction with the Japanese Society of Hypertension will herein review current knowledge on the role of endothelial dysfunction in conditions in which the renal vasculature is deeply affected, such as diabetes mellitus, preeclampsia, kidney transplantation, hyperhomocysteinemia and cancer. The few randomized controlled clinical trials (RCTs) that explored the concept that strategies aimed at correcting endothelial dysfunction in patients with hypertension and/or CKD are also discussed alongside their cardiovascular and renal outcomes.
DIABETIC NEPHROPATHY
Diabetic nephropathy, one of the main preventable causes of reno-parenchymal hypertension and CKD, is characterized by focal and segmental glomerulosclerosis [3] , which involves multiple factors including progressive podocyte injury, glomerular fibrosis and loss of glomerular filtration function [4, 5] , leading to proteinuria, and ultimately to the need for renal replacement therapy [4] (Fig. 1 ). Proteinuric CKD, and particularly end-stage renal disease (ESRD), not only aggravates hypertension and cardiovascular risk [6] , but also poses an economic rapidly growing burden to society [4] , making prevention of this disease a critical task for the future.
The pathogenesis of diabetic nephropathy not only involves hyperglycemia and inflammation, but also endothelial and nonendothelial pathways [7, 8] , including enhanced oxidative stress, renin-angiotensin-aldosterone system (RAAS) and endothelin-1 (ET-1) activation, and inflammatory processes that were discussed in Part I [4] .
Obesity, which is frequently associated with insulin resistance and/or diabetes, also leads to focal and segmental glomerulosclerosis, a condition termed 'obesity nephropathy'. Of note, practically all of the aforementioned endothelial mediators of CKD are also implicated in the pathogenesis of diabetic nephropathy [9] , as they were found to promote and maintain podocyte injury and glomerular and vascular inflammation [6, 10] . Hence, not unsurprisingly, as hypertension is common among these patients, antihypertensive medications targeting endothelial pathways, such as angiotensin I converting enzyme (ACE) inhibitors, angiotensin AT 1 receptor blockers (ARBs) or mineralocorticoid receptor antagonists, have been investigated in diabetic nephropathy. These agents were shown to improve clinical outcome with benefit that exceeded that attributable to changes in blood pressure (BP) [7, [11] [12] [13] [14] . Of note, the protective effects of ACE inhibitors and ARBs were particularly marked in obesity nephropathy [15] and predictably found to be largely BPindependent [11, 13, 14] , consistent with suggesting their direct renoprotective effects [7] .
It has been known for some time that kidney transplantation not only normalizes BP but also reverses hypertensive damage in the heart and retinal arteries of patients with proteinuric renal disease and hypertension [16] , indicating the reversibility of end-organ injury. Similarly, regression or partial disease remission was suggested to occur in patients with diabetic nephropathy treated with ARBs or ACE inhibitors, in whom proteinuria decreased [7] . Reversal of diabetic or nondiabetic focal and segmental glomerulosclerosis and/or proteinuria has also been observed in studies with endothelin receptor antagonists, both experimentally and clinically [17] [18] [19] . Currently, a novel approach to interfere with progression of diabetic nephropathy under investigation entails the pharmacological inhibition or downregulation of reactive oxygen species (ROS) generating NADPH oxidases enzymes [20, 21] (https://clinicaltrials.gov/ct2/show/NCT02010242).
Statins have also been shown to inhibit inflammatory activation in both endothelial cells and the vasculature [8] , but so far the clinical trials conducted in patients with diabetic nephropathy have failed to prove their beneficial effect on the natural history of the disease [6] .
Finally, strategies employing preventive measures, such as weight loss/bariatric treatment of obesity [8] , lifestyle changes to improve and maintain cardiorespiratory fitness or pharmacological interventions, such as antidiabetic therapy or those targeting the aforementioned endothelial mediators can conceivably reduce BP, delay vascular and renal aging, and thus contribute to an improved overall cardiovascular outcome [8, [22] [23] [24] [25] [26] [27] [28] [29] [30] .
PREECLAMPSIA-ASSOCIATED KIDNEY INJURY
Preeclampsia is the most frequent (prevalence about 3-8%) serious medical complication of pregnancy. It develops through two stages [31, 32] : in stage 1, aberrant shallow cytotrophoblast invasion in the maternal spiral arteries supplying the placenta results in poor placentation; in stage 2, this leads to repeated periods of placental hypoxia and reperfusion injury, resulting in oxidative stress and an increased production of placental factors (Fig. 2) . Among the latter, soluble fms-like tyrosine kinase 1 (sFlt-1), a splice variant of the membrane-bound vascular endothelial growth factor (VEGF) type 1 receptor originating from placental syncytiotrophoblast, has been widely studied.
Others include soluble endoglin, agonistic autoantibodies to the AT 1 receptor, and inflammatory cytokines [33, 34] . All these factors, likely in combination with an altered immune system in preeclampsia [35, 36] , are thought to contribute to generalized endothelial dysfunction, although their precise roles remain unclear. For example, in preeclamptic women, both circulating sFlt-1 and ET-1 levels rise progressively in relation to the severity of preeclampsia [37, 38] . These factors affect not only growth and development of the placenta and the fetus, but also the health of endothelial cells and kidney function, including the maintenance of the glomerular filtration barrier [39] . Moreover, elevated sFlt-1 levels, by binding both free VEGF and placental growth factor, disturb the balance between proangiogenic and antiangiogenic factors. Hence, these mechanisms may contribute to hypertension and renal damage in preeclampsia [35] .
Accordingly, as discussed below, treatment of cancer patients by blocking angiogenesis via VEGF inhibition (with tyrosine kinase inhibitors, and direct VEGF inhibition or inactivation) resulted in a preeclampsia-like syndrome, featuring hypertension, proteinuria and glomerular endotheliosis [40] . Moreover, VEGF inhibitor-treated cancer patients, like preeclamptic women, display high ET-1 levels, which correlated closely with the degree of VEGF inhibition, as estimated by either the serum sFlt-1 levels or the VEGF inhibitor dose [37] . Multiple regression analysis has pointed to a role for ET-1 as an independent determinant not only of the BP rise and proteinuria, but also of renin suppression in preeclamptic women [37] . Therefore, ET-1 activation seems to be involved in causing both the clinical manifestations of preeclampsia, and the well known paradoxical suppression of renin in this disease. ET-1 additionally acts as an aldosterone secretagogue via endothelin type B (ET B ) receptors [41] , whereas autoantibodies to AT 1 receptors, may have similar effects. Obviously, these antibodies should also suppress renin release via AT 1 receptor activation. Consequently, theoretically preeclamptic women would be expected to display an increased aldosterone/renin ratio, due to the opposite effects of FIGURE 2 Endothelial dysfunction and abnormal placentation in preeclampsia. During normal placentation, cytotrophoblast cells invade the maternal decidual arteries, remodeling them into high-capacitance vessels that supply the placenta and fetus with maternal oxygen and nutrients. In preeclampsia, this process is aberrant. The invasion of the trophoblasts is incomplete, with cytotrophoblast cells only in the superficial layers of the decidua, and the spiral arteries maintain features of high-resistance vessels (stage 1). Shallow trophoblasts invasion leads to placental hypoxia and reperfusion injury, with increased oxidative stress and production of placental factors, mainly soluble fms-like tyrosine kinase 1 (stage II). Soluble fms-like tyrosine kinase 1, combined to soluble endoglin, agonistic autoantibodies to the AT 1 receptor and inflammatory cytokines, causes endothelial dysfunction, finally leading to arterial hypertension and kidney damage in the mother and growth retardation in the fetus.
ET-1 and autoantibodies on renin and aldosterone, but, in contrast with this prediction, no such increase was observed [37] , suggesting that multiple complex mechanisms modulate the effects of ET B receptors and autoantibodies in vivo. A possible explanation is that the VEGFinduced increase in adrenal capillary density, which in normal pregnancy upregulates aldosterone production, is disturbed in preeclampsia because sFlt-1 blocks such effects of VEGF [42] .
Animal models of preeclampsia support the importance of sFlt-1/ET-1 upregulation in that ET-1 receptor blockade alleviates preeclampsia symptoms, in keeping with the effects seen with these agents in VEGF inhibitor-induced hypertension [37, 43, 44] . The cause of the rise of ET-1 in preeclampsia remains to be determined. Although acute VEGF inhibition in human umbilical vein endothelial cells did not affect ET-1 release [45] , soluble endoglin has been suggested to induce endothelial ET-1 production [46] . If confirmed, this could lead to the development of entirely new treatment targets. Endothelin receptor antagonism, having been linked to teratogenicity, might be feasible only at a late pregnancy stage, when all organs have been formed.
KIDNEY TRANSPLANTATION AND TRANSPLANT-ASSOCIATED HYPERTENSION
The global burden of ESRD patients needing renal replacement therapy and transplantation is continuing to rise. This poses a huge financial burden to healthcare systems [47] , which will continue to rise with improved survival from cardiovascular disease in these patients. Endothelial dysfunction is held to be central to both CKD development and the cardiovascular continuum as discussed in Part I [48] . Renal transplanted patients are no exception to this, which is clearly understandable given that circulating immune response cells find the endothelium as the first barrier to their attack on the transplanted organ. Although advances in the treatment of acute rejection and short-term graft survival now allow a 90% survival at 1 year [49] , long-term success has been more difficult to achieve. Oxidative stress is enhanced in recipients of kidney transplants and starts before transplantation while these patients develop ESRD. It is then aggravated during the ischemia-reperfusion occurring during the grafting, and then further exacerbated as a consequence of long-term immunosuppressant treatment, more with cyclosporine, which causes hypertension and renal damage, than with the newer immunosuppressive drugs like tacrolimus [50] . Moreover, several factors involved in the impaired vasorelaxation of transplanted patients, including ET-1 (see below), asymmetric dimethylarginine (ADMA) and fibroblast growth factor 23 (FGF23) (see section on vitamin D), are held to contribute to renal damage [51, 52] .
After hepatic, cardiac and renal transplantation, circulating levels of ET-1 increase [53] [54] [55] [56] , indicating systemic activation of the ET system and decreased ET B receptormediated ET-1 clearance. Accordingly, impaired endothelial cell function associated with ET-1 activation has been observed in human allograft recipients [57] . Cyclosporine is not only a potent stimulus for ET-1 production [58] , but also an inhibitor of the L-arginine/nitric oxide (NO) pathway [59] ; thereby, it contributes to post-transplant hypertension [60] . Moreover, endothelin type A (ET A ) receptor expression increases in renal allografts [61] and endothelin receptor antagonist (ERA) treatment effectively suppresses fibrotic and proliferative responses in several allografts [62] [63] [64] [65] [66] [67] [68] [69] [70] . Accordingly, selective ET A [71, 72] , but not mixed ET A /ET B blockade [73] , largely prevents chronic rejection and renal allograft injury, even in the absence of continued immunosuppression [71] through mechanisms not improved by ARB treatment [74] , suggesting that ERA have pronounced and independent immunomodulatory effects in the transplant recipient [75] . However, findings were mostly obtained in experimental models [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] , whereas RCTs [53] [54] [55] [56] [57] [58] [59] [60] [61] were too small to recommend a specific class of drugs to transplant-associated hypertension.
ANGIOGENESIS ANTAGONISTS AND THE RENAL ENDOTHELIN SYSTEM
Angiogenesis is a key process for tumor growth and metastatic spread. This has led to the development and introduction in the clinic of a large number of agents (such as anti-VEGF antibodies and small, orally active receptor tyrosine kinase inhibitors that block the VEGF signaling pathway) aimed at blunting the actions of VEGF. The latter regulates angiogenesis through endothelial cell proliferation and can play an important role in capillary repair in damaged glomeruli [76] . Common adverse effects of these agents are hypertension and kidney injury, which resemble the manifestations of preeclampsia, in which the release of sFlt-1 in the bloodstream, by sequestering VEGF and placenta growth factor, is held to produce an anti-angiogenic state [77] . As in preeclampsia, activation of the ET system occurs in cancer patients treated with the receptor tyrosine kinase inhibitors sunitinib and regorafenib [45, 78] . In pregnant rats, the anti-angiogenic factor sFlt-1 causes a rise in BP and expression of the prepro-ET-1 gene in the renal cortex [79] . Moreover, over expression of sFlt-1 in mice also increases expression of the genes encoding for ET-1 and the ET A receptor, effects that are amplified in endothelial NO synthase (eNOS)-deficient mice [80] . Thus, inhibition of angiogenesis leads to ET-1 activation, particularly when NO bioactivity is blunted. Accordingly, sunitinib dosedependently increased plasma ET-1 levels in rats, but unexpectedly did not increase the urinary excretion of ET-1, a marker of renal ET-1 production [81] . Moreover, opposite to what is seen with sFlt-1 administration in pregnant rats, expression of the prepro-ET-1 and endothelin converting enzyme genes were not increased. Notwithstanding this, the non-selective ERA macitentan prevented the rise in BP and proteinuria in sunitinib-exposed rats [82] , whereas amlodipine, which similarly lowered BP, did not affect proteinuria [82] .
In summary, even though the effects of sFlt-1 and sunitinib on renal expression of the prepro-ET-1 gene may not be uniform, it can be concluded that antiangiogenic treatment activates the ET-system and that data with ERA treatment support a role of the ET-system in Endothelial factors and CKD: role in disease conditions the development of proteinuria following antiangiogenic treatment.
HYPERHOMOCYSTEINEMIA, ENDOTHELIAL DYSFUNCTION AND RENAL DAMAGE
Hyperhomocysteinemia defined as a total plasma homocysteinemia more than 15 mmol/l, affects 5-7% of the general population and 20-40% of those with coronary atherosclerosis [83, 84] . It usually derives from a geneenvironment interaction involving a low folate intake and the presence of variants of the methylene-tetrahydro-folatereductase (MTHFR) gene (ID 4524), particularly in elderly people and in the presence of reduced GFR [85, 86] . Two non-synonymous single nucleotide polymorphisms for the MTHFR gene have been described: C677T in exon 4 (Ala222Val) that results in a MTHFR variant with decreased stability to temperature (thermolabile variant), and an A1298C (Glu429Ala) in exon 7 that impairs MTHFR activity, albeit to a lesser extent than C677T [87] . These variants, in the presence of a low-folate supply, lead to hyperhomocysteinemia, which detrimentally affects the endothelium by inducing oxidative stress, with ensuing decreased NO production and NO bioactivity [88] , and also accumulation of the endogenous NOS inhibitor ADMA [89] .
Declining renal function, alongside aging and left ventricular systolic dysfunction, are recognized factors associated with hyperhomocysteinemia. ESRD patients are expected to develop hyperhomocysteinemia, as the kidney is the major site of homocysteine metabolism, and, moreover, dialysis is associated with loss of water-soluble B vitamins, which are key for maintaining normal plasma homocysteine levels [90] . Hyperhomocysteinemia induces severe oxidative stress, thus leading to oxidation of free or protein-bound thiols and aggravation of endothelial dysfunction [90, 91] . Accordingly, the MTHFR gene variants have been linked to kidney damage: the C677T variant was found to be associated with CKD in both the crosssectional Japan Multi-institutional Collaborative Cohort Study [92] and with mortality risk in ESRD patients of the Homocysteinemia in Kidney and End Stage Renal Disease-DNA study [93] . An association was also found between the decline of GFR and A1298C variant in the longitudinal African-Americans Study of Kidney Disease and Hypertension Trial [94] .
A recent Cochrane analysis of six studies on the effects of folic acid or vitamins B6 and vitamin B12 in ESRD patients, however, failed to show a decrease in cardiovascular events and/or death, leading the contention that homocysteinelowering therapies should not be used for cardiovascular risk reduction [95] . This conclusion, however, cannot be taken for granted for the following reason. As there is a linear relationship between plasma homocysteine and risk of cardiovascular events over the entire range of plasma homocysteine values, a benefit from lowering homocysteine may be expected only in those who have overt hyperhomocysteinemia before they develop ESRD [84] and not in the population at large in which the beneficial effect occurring in a subset of the patients can be markedly diluted. In keeping with this prediction, a recent large study in patients with mild-to-moderate CKD found that the combined treatment with enalapril and folic acid supplementation delayed the progression of CKD, as compared with enalapril alone [96] . The concept that lowering plasma hyperhomocysteinemia is beneficial is further supported by evidence that folic acid supplementation protected from cardiovascular diseases patients with low folic acid levels and without preexisting cardiovascular disease [97] .
ENDOTHELIAL FACTORS, KIDNEY PROTECTION AND DISEASE PREVENTION
In this era of evidence-based medicine, RCTs are the basis for high level evidence and Class I recommendations. Whether specifically targeting endothelial dysfunction may ultimately improve cardiovascular and renal outcomes in hypertension and CKD patients remains to be demonstrated in adequately designed, long-term RCTs. As a proofof-principle, a study that used a remote ischemic preconditioning strategy to improve endothelial function reported prevention of acute kidney injury in high-risk patients undergoing cardiac surgery (mean eGFR 56 ml/min per 1.73 m 2 ) [98] , thus supporting the contention that endothelial factors may be targets for kidney protection in humans [99] .
We suggest that a holistic approach to treat hypertension, dyslipidemia and diabetes mellitus (with/without diabetic nephropathy) should be the optimal strategy to prevent CKD, or at least retard its progression. However, studies involving specific targets suggests the possibility of achieving additional benefits. For example, in four small trials, the addition of spironolactone for 60 days, on top of RAAS inhibition, reduced microalbuminuria, and decreased BP and eGFR, without altering plasma biomarker concentrations of endothelial dysfunction [100] . Aldosterone breakthrough may occur in patients with diabetic nephropathy treated with an ACE inhibitor or an ARB, likely because the secretion of aldosterone is controlled by multiple mechanisms, besides Ang II [101, 102] . Notably, aldosterone breakthrough has been associated with worsening of microalbuminuria [103] , which might explain why low-dose spironolactone (25 mg/day) on top of standard antihypertensive treatment reduced microalbuminuria despite no significant BP changes [104] . Moreover, spironolactone induced a sustained antiproteinuric effect when added on top of an ACE inhibitor or an ARB in a longer (1-year) study [103] . Similarly, in a larger RCT, eplerenone (50-200 mg/day) was more effective in reducing microalbuminuria than amlodipine in spite of similar lowering BP and pulse pressure in patients with systolic hypertension [105] .
In CKD patients, the use of mineralocorticoid receptor antagonists, especially if combined with ACE inhibitors and/or ARBs, has been limited by the fear of hyperkalemia [106, 107] . However, serious hyperkalemia developed in less than 1% of the patients with nondiabetic I-III CKD stages (eGFR 30-89 ml/min per 1.73 m 2 ) receiving 25 mg spironolactone on top of ARB or ACE inhibition, whereas a significant decrease in urinary albumin excretion greater or equal to 50% was observed in 35% of the patients [108] . Nonetheless, even though in most cases mineralocorticoid receptor antagonists are effective and well tolerated [109] , caution should be exercised in prescribing these agents to CKD patients with an eGFR less than 45 ml/min per 1.73 m 2 and serum K þ levels more than 4.5 mmol/l on appropriately dosed diuretic treatment, as these features predict the development of hyperkalemia.
Several small-sized short-term RCTs were performed to target the molecular pathways involved in endothelial dysfunction in CKD and hypertension [110] [111] [112] [113] [114] . In an attempt to improve endothelial function using antioxidant therapy, a double-blind pilot RCT was performed in nine CKD patients with stable chronic heart failure, treated with placebo or N-acetylcysteine (500 mg orally twice daily) for 28 days followed by a wash-out period (>7 days) and cross-over to the other treatment. This study showed that N-acetylcysteine therapy was associated with improved forearm blood flow after ischemia caused by supra-systolic pressure of 200 mmHg [110] .
Cilostazol, a phosphodiesterase inhibitor with antiplatelet/antithrombotic effects, used in chronic peripheral arterial disease, induces vasodilatation and inhibits vascular smooth muscle cells proliferation [111] . In a small singleblinded study, patients with peripheral arterial disease and diabetic nephropathy [baseline eGFR of 73 (placebo)-77 (cilostazol) ml/min per 1.73 m 2 ] were randomized to oral cilostazol (100 mg b.i.d.) or placebo for 1 year. Microalbuminuria and albumin-creatinine ratio were significantly reduced in the cilostazol group as compared with the placebo group, alongside a decrease in the plasma concentration of endothelial (leukocyte adhesion molecules) markers E-selectin and vascular cell adhesion molecule-1 (VCAM-1), but no changes in BP or eGFR [111] .
Phosphodiesterase type 5 (PDE5), expressed in endothelial, glomerular, mesangial, cortical tubular and inner medullary collecting duct cells, degrades cyclic guanosine monophosphate, and experimental data suggest that PDE5 inhibitors can be useful in preventing CKD. Sildenafil, one PDE5 inhibitor, prevented glomerular hypertension and hyperfiltration in rats with subtotal nephrectomy [115, 116] and reduced protein excretion in streptozotocin-induced diabetes [117] ; it also improved flow-mediated vasodilation in diabetic men [118, 119] . Vardenafil, another PDE5 inhibitor, also reduced proteinuria in rat streptozocininduced type 1 diabetes mellitus, and restored nephrin and podocin expression in podocytes [120] . Whether these agents help in maintaining the kidney function in patients remains to be tested in long-term RCTs.
ADMA is a by-product of the methylation of arginine residues, which acts as a competitive inhibitor of L-arginine to reduce NO production, and also causes decoupling of eNOS leading to ROS production instead of NO [121] . The circulating levels of ADMA are increased in CKD in proportion to the severity of renal impairment and predict cardiovascular outcomes [122] . Oxidative stress also increases ADMA concentration by upregulating the synthetic enzyme protein arginine methyltransferase-1 and downregulating dimethylarginine dimethylaminohydrolase, the enzyme degradating ADMA [123] . Vitamin E supplementation and (transiently) intravenous ascorbic acid level reduce ADMA levels in patients with CKD [124] , suggesting that this may represent an important mechanism by which antioxidants exert a beneficial cardiovascular effect.
High uric acid levels promote oxidative stress and might induce endothelial dysfunction. However, few studies that investigated if allopurinol could restore endothelial function in hyperuricemic patients, have given quite heterogeneous results, with some suggesting a benefit and others no effect [112, 125, 126] .
VITAMIN D, ENDOTHELIAL FUNCTION AND KIDNEY PROTECTION
Endothelial cells not only express the vitamin D receptor, but also respond to calcitriol, the active form of vitamin D. A placebo-controlled RCT investigated the effect of a 12-week treatment with calcitriol on endothelial function in patients with stage 3-4 CKD [127] .
The vitamin D receptor activator paricalcitol, given at a dose (2 mg/day) that did not affect endothelium-independent vasodilation and BP, improved endothelium-dependent vasodilation, and slightly lowered eGFR [À3.2 ml/min per 1.73 m 2 (À4.9 to À1.4), P < 0.001], two beneficial effects that disappeared after drug withdrawal [127] . Significantly, the beneficial effect of paricalcitol was maximal in patients with no or minimal changes in serum phosphate levels and was abolished in patients with hyperphosphatemia. Hence, the endothelium-protective effect of vitamin D receptor activation might be potentiated by phosphate lowering interventions [113] .
Another RCT using placebo, 1 or 2 mg of paricalcitol daily for 3 months in 36 nondiabetic CKD patients (mean eGFR 40 ml/min per 1.73 m 2 ) reported a decline in endothelial function, which occurred in the group receiving the highest dose of paricalcitol, with no changes in BP, eGFR and microalbuminuria [128] . By contrast, in a double-blind, placebocontrolled RCT conducted in patients with type 2 diabetes and stage 3 or 4 CKD, paricalcitol 1 mg daily had no effect on endothelial function, measured by brachial artery flowmediated dilation, or plasma biomarkers of inflammation and oxidative stress. A smaller RCT performed with oral ergocalciferol, or placebo, over 6 months, in patients with nondiabetic CKD stage 3-4 and concomitant vitamin D deficiency, showed that a high-dose ergocalciferol therapy improved microcirculatory function and reduced oxidative stress, without altering BP, eGFR or albuminuria [129] .
In a small RCT, phosphate-lowering treatment with sevelamer improved flow-mediated vasodilatation and FGF23 levels, alongside flow-mediated vasodilatation [130] . FGF23 is a hormone-regulating serum phosphate and vitamin D, whose plasma levels are markedly elevated in patients with CKD [130] . The findings of the RCT, along with the evidence that FGF23 impairs vasorelaxation by decreasing NO bioavailability [131] , suggest that FGF-23 contributes to vascular dysfunction in patients with stage 4 CKD and, therefore could be a target for pharmacologic intervention. However, larger and longer intervention studies are necessary to determine whether there is a protective effect of vitamin D and/or other factors affecting calcium/ phosphate metabolism on the kidney.
CONCLUSION AND RECOMMENDATIONS
Diabetes mellitus, preeclampsia, solid organ transplantation, hyperhomocysteinemia and antiangiogenic therapy in cancer are all factors that deeply affect endothelial function favoring the development of kidney damage and amplifying injury primarily induced by metabolic abnormalities. As in all diseases, a better understanding of the underlying mechanisms will improve prevention and treatment of kidney disease. However, so far translation of new generated knowledge into clinical practice has been slow with current pharmacologic tools, likely because of the difficulty of disentangling the relative role of each putative pathogenic factor. Hence, further specific research is needed particularly in the field of RCTs focused at testing strategies for preserving endothelial function and GFR. To this end, this working group welcomes and supports the planning of integrated research efforts from all investigators who share an interest for the endothelium and preservation of renal health.
